ClinicalTrials.gg
CompletedNCT07941271Updated Nov 17, 2026

Nut Supplementation in Inflammatory Bowel Disease: A Proof-of-Concept Study of Gut Microbiome and Metabolome Effects

An interventional study of Mixed Nut Blend in Inflammatory Bowel Diseases (IBD), Crohn Disease (CD) and Ulcerative Colitis (UC), sponsored by Sheba Medical Center. Completed at 1 site in Israel. Open to participants aged 10 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Sheba Medical Center · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Feb 2025, registered Nov 2026).
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Inflammatory Bowel Diseases with a site in Israel — 9 open to participants now, 12 under way, 5 of them phase 3. Inflammatory Bowel Diseases · Israel.

Enrollment
34th of 51
60 · median 100
Started
2025
with 4 others
No phase
22 of 69
2 open now
Registered
69th of 69
by date
Lead sponsor
4 of 69
Sheba Medical Center

Among the 69 studies in Inflammatory Bowel Diseases with a site in Israel, this one is the 34th largest by enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2025, is one of 22 with no phase, and was the 69th registered.

Inflammatory Bowel Diseases

1,552 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

9 of the 69 studies in Inflammatory Bowel Diseases with a site in Israel are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 275 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 115 (42%) stop at 75 or younger; 76 take children under 18; 60 take healthy volunteers.

This study: 10 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Inflammatory Bowel Diseases with a site in Israel, or all of them as a file.
02

Study summary

People with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, often continue to experience disruptions in the gut microbiome and metabolism even when their disease is in clinical remission on biologic therapy. These persistent gut-level changes may contribute to disease flares over time.

Nuts are nutrient-dense foods rich in unsaturated fats, fiber, minerals, and polyphenols, and have been shown to support gut health in general and cardiometabolic populations. However, their specific effects on the gut microbiome and metabolome in people with IBD in remission have not been examined.

This proof-of-concept study investigated whether short-term, daily consumption of a standardized mixed nut blend (almonds, walnuts, and pecans) shifts the gut microbiome and metabolic signals of people with IBD toward a healthier, control-like profile.

Sixty participants: 21 healthy controls, 19 participants with Crohn's disease in remission, and 20 participants with ulcerative colitis in remission, underwent a 3-day nut-avoidance washout, followed by 10 days of consuming 30 g/day of a mixed nut blend. Fecal samples were collected on days -3, 0, 5, and 10 and analyzed for microbiome composition (16S rRNA sequencing) and metabolite profiles (untargeted LC-MS metabolomics). Participants also completed a food frequency questionnaire and a daily adherence survey.

The study aimed to characterize how a defined, single food item influences gut health signals in IBD remission, providing a foundation for larger, longer-term dietary interventions.

03

Conditions studied

  • Inflammatory Bowel Diseases (IBD)
  • Crohn Disease (CD)
  • Ulcerative Colitis (UC)

Keywords

  • Nuts
  • Inflammatory bowel disease
  • Butyrate-producing bacteria
  • Multi-omics
  • Omega-3 fatty acids
  • Dietary intervention
  • Gut microbiome
  • Fecal metabolomics
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Crohn's disease or ulcerative colitis in clinical remission, as determined by the treating physician
  • Non-IBD volunteers (controls)
  • Willingness and ability to provide written (and parental/guardian consent for minors)

Exclusion criteria

Exclusion Criteria:

  • Active Crohn's disease or ulcerative colitis
  • Known nut allergy
  • Systemic antibiotic use within 4 weeks preceding enrollment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Mixed Nut Supplementation

    All participants received a defined mixed nut blend consisting of equal weights of raw almonds, walnuts, and pecans (10 g of each per daily portion, 30 g total) for 10 consecutive days, following a 3-day nut-avoidance washout period. Portions were pre-weighed, homogenized, sealed in dedicated single-use bags labeled with the intervention day, and distributed to each participant in a coded box of 10 bags.

    Dietary Supplement: Mixed Nut Blend

Interventions

  • Dietary supplementMixed Nut Blend

    30 g/day of a raw mixed nut blend (10 g each of almonds, walnuts, and pecans), consumed daily for 10 days after a 3-day nut-avoidance washout. The intervention was open-label and not accompanied by any additional dietary restriction.

06

What researchers measure

Primary outcomes

  1. Change in gut microbial composition following nut supplementation in IBD participants

    Paired within-subject changes in gut microbial composition in IBD participants (combined Crohn's disease and ulcerative colitis), comparing pre-intervention time points (Days -3 and 0) to during-intervention time points (Days 5 and 10). Assessed by 16S rRNA amplicon sequencing of fecal samples.

    Time frame: Days -3, 0, 5, and 10

  2. Change in fecal metabolite profile following nut supplementation in IBD participants

    Paired within-subject changes in the fecal metabolite profile of IBD participants (combined Crohn's disease and ulcerative colitis), comparing pre-intervention (Day 0) to during-intervention (Days 5 and 10) time points. Assessed by untargeted LC-MS metabolomics.

    Time frame: Days 0, 5, and 10

Secondary outcomes

  1. Directional shift of intervention-induced changes toward the non-IBD control profile

    Whether intervention-induced changes in gut microbial and fecal metabolite profiles of IBD participants move in a direction similar to patterns observed in participants without IBD at baseline. Assessed by comparing the direction of change (effect size) of significantly altered features during the intervention against their baseline differences between IBD and non-IBD controls.

    Time frame: Baseline (Days -3 and 0) and during intervention (Days 5 and 10)

07

Study locations

1 site
  • Sheba Medical Center
    Ramat Gan, 5265601, Israel
08

References and documents

Individual participant data

Plan to share: Yes — De-identified participant-level data will be made available upon publication of the primary manuscript, including microbiome composition (16S rRNA sequencing), fecal metabolite profiles, and dietary intake data, as Supplementary Datasets. Raw 16S amplicon sequencing data have been deposited in the NCBI BioProject repository under accession number PRJNA1522179.

Time frame: Available upon publication of the primary study manuscript

Access criteria: Raw 16S sequencing data are publicly available via NCBI BioProject (PRJNA1522179). Participant-level analytical datasets will be made available as Supplementary Datasets with the published manuscript.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Sep 2025, 6 months.

Of 283 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 6 months is below that.

Counting every sponsor, half of 297 studies reached it within 26 months; a quarter within 14 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartActual
Feb 27, 2025
Primary completionActual
Sep 25, 2025
CompletionActual
Sep 25, 2025
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941271
Collaborators
The Gertner Institute, Technion, Israel Institute of Technology
Responsible party
Yael Haberman (Physician-Scientist, Principal Investigator, Pediatric Gastroenterologist, Sheba Medical Center) — Principal investigator
First posted
Nov 17, 2026
Start date
Feb 27, 2025
Primary completion
Sep 25, 2025
Completion
Sep 25, 2025
Last update
Nov 17, 2026

Study contacts

Yael Haberman, MD, PhD
principal investigator · Sheba Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion